EP3632413A4 - Long-circulating liposome modified with c(rgd-acp-k) - Google Patents

Long-circulating liposome modified with c(rgd-acp-k) Download PDF

Info

Publication number
EP3632413A4
EP3632413A4 EP18806024.8A EP18806024A EP3632413A4 EP 3632413 A4 EP3632413 A4 EP 3632413A4 EP 18806024 A EP18806024 A EP 18806024A EP 3632413 A4 EP3632413 A4 EP 3632413A4
Authority
EP
European Patent Office
Prior art keywords
rgd
acp
long
circulating liposome
liposome modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18806024.8A
Other languages
German (de)
French (fr)
Other versions
EP3632413A1 (en
Inventor
Qiang Zhang
Cuishuan Wu
Yue SU
Changjin Lee
Guanghua CUI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Greatsun Bio Pharm Tech Co Ltd
Original Assignee
Beijing Greatsun Bio Pharm Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Greatsun Bio Pharm Tech Co Ltd filed Critical Beijing Greatsun Bio Pharm Tech Co Ltd
Publication of EP3632413A1 publication Critical patent/EP3632413A1/en
Publication of EP3632413A4 publication Critical patent/EP3632413A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18806024.8A 2017-05-25 2018-05-24 Long-circulating liposome modified with c(rgd-acp-k) Pending EP3632413A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710379667.0A CN108926719B (en) 2017-05-25 2017-05-25 Long-circulating liposomes modified with c (RGD-ACP-K)
PCT/CN2018/088251 WO2018214944A1 (en) 2017-05-25 2018-05-24 Long-circulating liposome modified with c(rgd-acp-k)

Publications (2)

Publication Number Publication Date
EP3632413A1 EP3632413A1 (en) 2020-04-08
EP3632413A4 true EP3632413A4 (en) 2021-03-10

Family

ID=64396251

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18806024.8A Pending EP3632413A4 (en) 2017-05-25 2018-05-24 Long-circulating liposome modified with c(rgd-acp-k)

Country Status (6)

Country Link
US (1) US11260068B2 (en)
EP (1) EP3632413A4 (en)
JP (1) JP7204744B2 (en)
KR (1) KR20200010510A (en)
CN (1) CN108926719B (en)
WO (1) WO2018214944A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113440610B (en) * 2021-08-30 2021-12-28 山东大学 Liposome carrying CD73 antibody and adriamycin together, preparation method and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756916B2 (en) 1998-11-12 2003-01-23 Jcr Pharmaceuticals Co., Ltd. Modulation of cell proliferative disorders by cyclic RGD
KR101376895B1 (en) * 2004-05-03 2014-03-25 헤르메스 바이오사이언스, 인코포레이티드 Liposomes useful for drug delivery
CN100431609C (en) 2005-04-11 2008-11-12 北京大学 Long circulation liposome with modified integrin and carried anticancer medicine for injection
US9295736B2 (en) 2007-09-24 2016-03-29 Bar Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
CN101327190B (en) * 2008-07-29 2011-04-27 北京大学 Anti-tumor long-circulating target liposomes for injections
CN102114000B (en) 2009-12-31 2013-08-21 复旦大学 Co-feeding lipid nano-delivery system for medicine carrying
CN103371975A (en) * 2012-04-16 2013-10-30 上海现代药物制剂工程研究中心有限公司 Targeted long-circulation liposome preparation and preparation method thereof
KR101375639B1 (en) 2012-05-16 2014-03-19 한국원자력의학원 Aminocyclopentane carboxylic acid-containing cyclo RGD derivatives, a process for the preparation thereof and a PET contrast agent comprising the same
KR101456233B1 (en) * 2012-08-09 2014-11-04 한국원자력의학원 Aminocyclopentane carboxylic acid-containing cyclo RGD derivatives, a process for the preparation thereof and a MRI contrast agent comprising the same
TW201519900A (en) * 2013-04-28 2015-06-01 Bayer Healthcare Llc Compositions and methods for inducing immune tolerance to coagulation factor proteins
US10428331B2 (en) * 2014-01-16 2019-10-01 Musc Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
CN106699845A (en) * 2015-11-12 2017-05-24 复旦大学 Stapled-RGD polypeptide, and applications thereof in tumor targeting delivery
CN105663043A (en) 2016-01-13 2016-06-15 无锡市妇幼保健院 131I-labelled c(RGDyk)-targeting doxorubicin thermosensitive nanoliposome and preparation and application thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BARDANIA HASSAN ET AL: "Encapsulation of eptifibatide in RGD-modified nanoliposomes improves platelet aggregation inhibitory activity", JOURNAL OF THROMBOSIS AND THROMBOLYSIS, vol. 43, no. 2, 24 October 2016 (2016-10-24), pages 184 - 193, XP036163414, ISSN: 0929-5305, [retrieved on 20161024], DOI: 10.1007/S11239-016-1440-6 *
CUITIAN CHEN ET AL: "Peptide-22 and Cyclic RGD Functionalized Liposomes for Glioma Targeting Drug Delivery Overcoming BBB and BBTB", ACS APPLIED MATERIALS & INTERFACES, vol. 9, no. 7, 9 February 2017 (2017-02-09), pages 5864 - 5873, XP055389560, ISSN: 1944-8244, DOI: 10.1021/acsami.6b15831 *
JANSSEN A P C A ET AL: "Peptide-targeted PEG-liposomes in anti-angiogenic therapy", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 254, 2003, pages 55 - 58, XP002497490, ISSN: 0378-5173, DOI: 10.1016/S0378-5173(02)00682-8 *
JI-AE PARK ET AL: "Synthesis and evaluation of new c(RGD) peptides for tumor-targeting PET imaging probe", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 56, no. Suppl.1, 12 May 2013 (2013-05-12), pages S206, XP055767769, ISSN: 0362-4803 *
PARK JI-AE ET AL: "Improved tumor-targeting MRI contrast agents: Gd(DOTA) conjugates of a cycloalkane-based RGD peptide", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 455, no. 3, 6 November 2014 (2014-11-06), pages 246 - 250, XP029108955, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2014.10.155 *
SCHIFFELERS R M ET AL: "Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin", JOURNAL OF CONTROLLED RELEASE, vol. 91, no. 1-2, 28 August 2003 (2003-08-28), pages 115 - 122, XP004447897, ISSN: 0168-3659, DOI: 10.1016/S0168-3659(03)00240-2 *
See also references of WO2018214944A1 *

Also Published As

Publication number Publication date
WO2018214944A1 (en) 2018-11-29
CN108926719B (en) 2020-09-01
KR20200010510A (en) 2020-01-30
US20200197424A1 (en) 2020-06-25
US11260068B2 (en) 2022-03-01
JP2020521004A (en) 2020-07-16
CN108926719A (en) 2018-12-04
JP7204744B2 (en) 2023-01-16
EP3632413A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
EP3529149A4 (en) Multicopter with angled rotors
EP3549340A4 (en) Multi-hypotheses merge mode
EP3589248A4 (en) Cryotherapies
EP3302435A4 (en) Liposome loading
EP3574400A4 (en) Cyber-retro-reflector technology
EP3643205A4 (en) Chair
EP3459756A4 (en) Counterfeit-preventing structure
EP3733849A4 (en) Improved promoter and use thereof
EP3605739A4 (en) Connection structure
EP3623027A4 (en) Assembly structure
EP3643204A4 (en) Chair
EP3903530A4 (en) Methods and devices for operating with dual connectivity
EP3729351A4 (en) Fast and partition-resilient blockchains
EP3643203A4 (en) Chair
EP3643206A4 (en) Chair
EP3632413A4 (en) Long-circulating liposome modified with c(rgd-acp-k)
KR200487012Y1 (en) Micro-diplexer with enhanced isolation and loss
EP3892371A4 (en) Functional structure
EP3818976A4 (en) Structure
EP3701119B8 (en) Well design and associated well structures
EP3723553A4 (en) Chair
EP3723552A4 (en) Chair
EP3486982A4 (en) Structure
EP3585947A4 (en) Embanking arrangement
EP3892376A4 (en) Functional structure

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210204

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/42 20170101ALI20210129BHEP

Ipc: A61K 47/62 20170101ALI20210129BHEP

Ipc: A61K 47/69 20170101AFI20210129BHEP

Ipc: A61P 35/00 20060101ALI20210129BHEP

Ipc: A61K 9/127 20060101ALI20210129BHEP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0009127000

Ipc: A61K0047690000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/704 20060101ALI20240322BHEP

Ipc: A61P 35/00 20060101ALI20240322BHEP

Ipc: A61K 47/42 20170101ALI20240322BHEP

Ipc: A61K 9/127 20060101ALI20240322BHEP

Ipc: A61K 47/62 20170101ALI20240322BHEP

Ipc: A61K 47/69 20170101AFI20240322BHEP

INTG Intention to grant announced

Effective date: 20240411